Ionis Pharmaceuticals Inc (IONS)

Jan 30, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by SG Americas Securities LLC - MarketBeat

Jan 30, 2025

Jan 29, 2025

Familial Chylomicronemia Syndrome FDA Approvals, Clinical - openPR

Jan 29, 2025

Jan 27, 2025

September 19th Options Now Available For Ionis Pharmaceuticals - Nasdaq

Jan 27, 2025

Jan 24, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Up 7%Time to Buy? - MarketBeat

Jan 24, 2025

Jan 24, 2025

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug - Yahoo Finance

Jan 24, 2025

Jan 24, 2025

What is Leerink Partnrs’ Forecast for IONS FY2024 Earnings? - Defense World

Jan 24, 2025

Jan 23, 2025

Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart

Jan 23, 2025

Jan 23, 2025

70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - Yahoo Finance

Jan 23, 2025

Jan 23, 2025

Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN

Jan 23, 2025

Jan 23, 2025

William Blair Brokers Increase Earnings Estimates for IONS - MarketBeat

Jan 23, 2025

Jan 23, 2025

Biogen/ Ionis Spinraza being reviewed for higher dose (BIIB) - Seeking Alpha

Jan 23, 2025

Jan 23, 2025

Leerink Partnrs Has Negative Outlook of IONS FY2024 Earnings - MarketBeat

Jan 23, 2025

Jan 23, 2025

Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St

Jan 23, 2025

Jan 23, 2025

Transthyretin Amyloid Cardiomyopathy Treatment Market - openPR

Jan 23, 2025

Jan 21, 2025

Assenagon Asset Management S.A. Raises Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Jan 21, 2025

Jan 21, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Assenagon Asset Management S.A. - Defense World

Jan 21, 2025

Jan 19, 2025

Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN

Jan 19, 2025

Jan 19, 2025

Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN

Jan 19, 2025

Jan 19, 2025

Ionis Pharmaceuticals exec sells $144,861 in stock - MSN

Jan 19, 2025

Jan 19, 2025

Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN

Jan 19, 2025

Jan 19, 2025

Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN

Jan 19, 2025

Jan 18, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat

Jan 18, 2025

Jan 18, 2025

Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat

Jan 18, 2025

Jan 18, 2025

Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN

Jan 18, 2025

Jan 18, 2025

Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia

Jan 18, 2025

Jan 18, 2025

Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia

Jan 18, 2025

Jan 18, 2025

Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN

Jan 18, 2025

Jan 18, 2025

Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN

Jan 18, 2025

Jan 17, 2025

Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN

Jan 17, 2025

Jan 17, 2025

Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia

Jan 17, 2025

Jan 17, 2025

Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025

Jan 17, 2025

Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa

Jan 17, 2025

Jan 17, 2025

Ionis Pharmaceuticals EVP sells $241,628 in stock By Investing.com - Investing.com Canada

Jan 17, 2025

Jan 17, 2025

EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow

Jan 17, 2025

Jan 17, 2025

Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow

Jan 17, 2025

Jan 17, 2025

EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow

Jan 17, 2025

Jan 17, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month LowTime to Sell? - MarketBeat

Jan 17, 2025

Jan 17, 2025

Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey

Jan 17, 2025

Jan 17, 2025

Familial Lipoprotein Lipase Deficiency Market to Continue - openPR

Jan 17, 2025

Jan 15, 2025

Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma - Barchart

Jan 15, 2025